Back to search results

CX11 for Obesity and Overweight

This study is testing different doses of CX11 tablets to see how safe they are and how well people tolerate them. You might be able to join if you are between 18 and 55 years old, and have obesity (BMI of 30.0 to 39.9 kg/m²) or are overweight (BMI of 27.0 to less than 30.0 kg/m²) with at least one weight-related health problem like prediabetes or high blood pressure. We're looking to see if CX11 helps with weight loss, specifically by measuring the percentage change in body weight after 26 weeks. The current recruitment status is unclear.

Study design
This is a Phase 1b study that will include about 90 participants. It is randomized, meaning you will be assigned to a group by chance, and placebo-controlled, meaning some participants will receive an inactive pill (placebo) instead of CX11.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main measurement for this study is taken at Week 26.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07652047

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Recruiting
PHASE1Ages 18–55InterventionalTreatment
Corxel Pharmaceuticals
~90 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:CX11Placebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage change in body weight from baseline
Measured over Week 26

Conditions

Obesity & Overweight

Explore related trials

ObesityOverweight

Where it's being run

2 sites across 2 states
Nevada1
Texas1

Who to contact

Study coordinator
[email protected]
201-268-3723
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female, 18-55 years.
BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
Able to comply with study procedures and reproductive requirements.

Exclusion

Diabetes or obesity due to endocrine/genetic causes.
Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.

What this trial measures

  • Percentage change in body weight from baselineWeek 26